China’s Mindray Gets U.S. FDA Clearance For New Imaging System
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has cleared a new type of ultrasound imaging system developed by China's Mindray Medical International. Mindray already had approval from China's State FDA and European regulators for its DC-3 color system used in abdominal, cardiac, endovaginal and OB/GYN treatments. The device is intended to complement its DC-6 and MS systems, but the difference is DC-3 is intended for the low-end markets. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.